BB Biotech AG

BB Biotech AG is a leading investment company specializing in the biotechnology sector. Established in Switzerland in 1993, it stands among the world’s largest and most experienced investors focused exclusively on biotech companies. BB Biotech AG primarily invests in listed firms developing and commercializing innovative drugs, with a particular emphasis on small and mid-cap companies headquartered in the United States and Western Europe. The portfolio typically centers around five to eight core holdings that represent the majority of asset value, complemented by a broader selection of additional biotech firms, and may include a limited allocation to private companies. The company’s investment strategy, overseen by a board with deep sector expertise and executed by Bellevue Asset Management AG, is grounded in rigorous fundamental research and targets long-term, long-only positions. BB Biotech AG plays a pivotal role in supporting the development of treatments for oncology, neurological, cardiovascular, metabolic, autoimmune, and infectious diseases, often capitalizing on transformative biotechnologies such as cell and gene therapy, as well as RNA-based approaches. The firm’s presence and influence contribute significantly to driving innovation within the healthcare and life sciences markets.